Structural basis for accelerated cleavage of bovine pancreatic trypsin inhibitor (BPTI) by human mesotrypsin
about
Functional and Structural Roles of the Cys14–Cys38 Disulfide of Bovine Pancreatic Trypsin InhibitorDeterminants of Affinity and Proteolytic Stability in Interactions of Kunitz Family Protease Inhibitors with MesotrypsinThe P 2 ′ residue is a key determinant of mesotrypsin specificity: engineering a high-affinity inhibitor with anticancer activityLong-range Electrostatic Complementarity Governs Substrate Recognition by Human Chymotrypsin C, a Key Regulator of Digestive Enzyme ActivationMatrix Metalloproteinase-10 (MMP-10) Interaction with Tissue Inhibitors of Metalloproteinases TIMP-1 and TIMP-2: BINDING STUDIES AND CRYSTAL STRUCTUREPresence versus absence of hydrogen bond donor Tyr-39 influences interactions of cationic trypsin and mesotrypsin with protein protease inhibitorsSequence and conformational specificity in substrate recognition: several human Kunitz protease inhibitor domains are specific substrates of mesotrypsin.Mesotrypsin Has Evolved Four Unique Residues to Cleave Trypsin Inhibitors as SubstratesAn Acrobatic Substrate Metamorphosis Reveals a Requirement for Substrate Conformational Dynamics in Trypsin Proteolysis.The amyloid precursor protein/protease nexin 2 Kunitz inhibitor domain is a highly specific substrate of mesotrypsin.Small molecule inhibitors of mesotrypsin from a structure-based docking screen.Complete analysis of the human mesotrypsinogen gene (PRSS3) in patients with chronic pancreatitis.Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109Mechanisms and specificity of factor XIa and trypsin inhibition by protease nexin 2 and basic pancreatic trypsin inhibitorTyrosine sulfation of human trypsin steers S2' subsite selectivity towards basic amino acids.Mesotrypsin Signature Mutation in a Chymotrypsin C (CTRC) Variant Associated with Chronic Pancreatitis.Combinatorial protein engineering of proteolytically resistant mesotrypsin inhibitors as candidates for cancer therapyPRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancerSerine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancersBiochemical and structural insights into mesotrypsin: an unusual human trypsin.Zymogen activation confers thermodynamic stability on a key peptide bond and protects human cationic trypsin from degradation.Complex Formation of Human Proelastases with Procarboxypeptidases A1 and A2.Multiple pathways are involved in DNA degradation during keratinocyte terminal differentiation.Purification and characterization of cocoonase from the silkworm Bombyx mori.Pre-equilibrium competitive library screening for tuning inhibitor association rate and specificity toward serine proteases.A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineeringMapping protein selectivity landscapes using multi-target selective screening and next-generation sequencing of combinatorial libraries
P2860
Q27651502-B2165C34-DE2F-454C-96CB-F9C022B0C5E5Q27664637-2F582448-EEF6-4719-AFFF-F7D2E0DD5070Q27671330-6D231811-2385-48B8-A3C5-BBA8C5B72DEEQ27676497-D4E78CEF-DB75-4790-A92C-B6E1C3C0CFA4Q27678085-604B3DFF-432A-4609-87AD-7CDCCEE60911Q27679201-165C7A7D-B072-4DF6-BD16-C6EEB42E9ABCQ30367678-E8F1E17B-8A5B-4329-BB84-7D94D0D72869Q30376720-E06B73D1-6112-46D8-A2CE-4BEA58EAFB2CQ30394859-77562274-2520-43E7-9086-799443C30586Q33581987-7381695C-31EC-4F7D-AF90-F263810F6DA9Q33626452-81B36051-87FF-49FB-A5D3-72F20527A424Q33970803-653F64E5-91B1-48C9-95A3-AAF3E12BCE61Q34088459-BED4C44C-E57F-4562-B4BA-91EFBBE6CB53Q34541270-4F9E7FDE-98C8-4121-A5EA-7B12A9144848Q35204469-7D5AF588-95B9-46C1-8155-193539379401Q35837145-4FA89CBF-8F6B-42EB-B973-EB7EC9971F6DQ35950487-C0213EFD-38F4-4F05-869C-3BE223AF18E4Q36493144-B27EC0F8-7C8D-4739-981E-F426A708AC96Q36546449-1681A789-DCA4-491C-B57C-D87DC9598DD7Q37180025-62132AFD-2142-4102-86D2-FD5A1CA1E9E4Q37596314-6525F1EF-F953-4972-A91A-9CC8BEB93DC1Q38760758-A8DA6B7B-ED5C-498D-8C5E-1AEB12351F99Q38993018-C6FD82ED-4FB6-41B7-AE59-30E6C70CCCABQ42002518-1F1717A8-7469-4C81-A956-E09EBA277C7BQ52657347-552CCD3D-B01D-4380-AF00-68BD6D64C21CQ56888917-D83CB01A-7842-46E5-8CE0-0A9D35B02A9FQ58695396-ADA29767-E58C-45B5-A0A1-9F9E5522E0B9
P2860
Structural basis for accelerated cleavage of bovine pancreatic trypsin inhibitor (BPTI) by human mesotrypsin
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Structural basis for accelerat ...... or (BPTI) by human mesotrypsin
@ast
Structural basis for accelerat ...... or (BPTI) by human mesotrypsin
@en
Structural basis for accelerat ...... or (BPTI) by human mesotrypsin
@nl
type
label
Structural basis for accelerat ...... or (BPTI) by human mesotrypsin
@ast
Structural basis for accelerat ...... or (BPTI) by human mesotrypsin
@en
Structural basis for accelerat ...... or (BPTI) by human mesotrypsin
@nl
prefLabel
Structural basis for accelerat ...... or (BPTI) by human mesotrypsin
@ast
Structural basis for accelerat ...... or (BPTI) by human mesotrypsin
@en
Structural basis for accelerat ...... or (BPTI) by human mesotrypsin
@nl
P2093
P2860
P356
P1476
Structural basis for accelerat ...... or (BPTI) by human mesotrypsin
@en
P2093
Alexandra Hockla
Alexei S Soares
Evette S Radisky
Moh'd A Salameh
P2860
P304
P356
10.1074/JBC.M708268200
P407
P577
2008-02-15T00:00:00Z